

**This is an electronic reprint of the original article.
This reprint *may differ* from the original in pagination and typographic detail.**

Author(s): Juvonen, Risto O.; Rauhamäki, Sanna; Kortet, Sami; Niinivehmas, Sanna; Troberg, Johanna; Petsalo, Aleksanteri; Huuskonen, Juhani; Raunio, Hannu; Finel, Moshe; Pentikäinen, Olli

Title: Molecular docking-based design and development of a highly selective probe substrate for UDP-glucuronosyltransferase 1A10

Year: 2018

Version:

Please cite the original version:

Juvonen, R. O., Rauhamäki, S., Kortet, S., Niinivehmas, S., Troberg, J., Petsalo, A., Huuskonen, J., Raunio, H., Finel, M., & Pentikäinen, O. (2018). Molecular docking-based design and development of a highly selective probe substrate for UDP-glucuronosyltransferase 1A10. *Molecular Pharmaceutics*, 15(3), 923-933.
<https://doi.org/10.1021/acs.molpharmaceut.7b00871>

All material supplied via JYX is protected by copyright and other intellectual property rights, and duplication or sale of all or part of any of the repository collections is not permitted, except that material may be duplicated by you for your research use or educational purposes in electronic or print form. You must obtain permission for any other use. Electronic or print copies may not be offered, whether for sale or otherwise to anyone who is not an authorised user.

Molecular docking-based design and development of a highly selective probe substrate for UDP-glucuronosyltransferase 1A10

Risto Olavi Juvonen, Sanna Rauhamäki, Sami Kortet, Sanna P. Niinivehmas, Johanna Troberg, Aleksanteri Petsalo, Juhani Huuskonen, Hannu Raunio, Moshe Finel, and Olli T. Pentikainen

Mol. Pharmaceutics, **Just Accepted Manuscript** • DOI: 10.1021/acs.molpharmaceut.7b00871 • Publication Date (Web): 08 Feb 2018

Downloaded from <http://pubs.acs.org> on February 12, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3 **Molecular docking-based design and development of a highly selective probe**
4
5 **substrate for UDP-glucuronosyltransferase 1A10**
6
7
8
9

10
11
12 ¹Risto O. Juvonen, ²Sanna Rauhamäki, ^{2,3}Sami Kortet, ²Sanna Niinivehmas, ⁴Johanna
13 Troberg, ¹Aleksanteri Petsalo, ³Juhani Huuskonen, ¹Hannu Raunio, ⁴Moshe Finel, ^{2,5}Olli T.
14 Pentikäinen
15
16
17
18
19
20
21

22 1 School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Box 1627,
23 FI-70211 Kuopio, Finland
24

25
26
27 2 University of Jyväskylä, Department of Biological and Environmental Science, P.O. Box
28 35, FI-40014 University of Jyväskylä, Finland
29
30

31
32 3 University of Jyväskylä, Department of Chemistry, P.O. Box 35, FI-40014 University of
33 Jyväskylä, Finland
34
35

36
37 4 Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of
38 Helsinki, P.O. Box 56, FI-00014 University of Helsinki, Finland
39
40

41
42 5 Institute of Biomedicine, Faculty of Medicine, University of Turku, FI-20014 University of
43 Turku, Finland
44
45

46
47
48
49
50
51 * Corresponding authors: risto.juvonen@uef.fi (in vitro), olli.pentikainen@utu.fi (modeling
52 and synthesis)
53
54
55
56
57
58
59
60

1
2
3 Keywords: 7-hydroxycoumarin, UDP-glucuronosyltransferase, glucuronidation, in silico,
4
5 fluorescence, drug metabolism
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Intestinal and hepatic glucuronidation by the UDP-glucuronosyltransferases (UGTs) greatly affect the bioavailability of phenolic compounds. UGT1A10 catalyzes glucuronidation reactions in the intestine, but not in the liver. Here, our aim was to develop selective, fluorescent substrates to easily elucidate UGT1A10 function. To this end, homology models were constructed, used to design new substrates and subsequently six novel C3 substituted (4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 4-dimethylaminophenyl, 4-methylphenyl or triazole) 7-hydroxycoumarin derivatives were synthesized from inexpensive starting materials. All tested compounds could be glucuronidated to non-fluorescent glucuronides by UGT1A10, four of them highly selectively by this enzyme. A new UGT1A10 mutant, 1A10-H210M, was prepared based on the newly constructed model. Glucuronidation kinetics of the new compounds, in both wild-type and mutant UGT1A10 enzymes, revealed variable effects of the mutation. All six new C3 substituted 7-hydroxycoumarins were glucuronidated faster by human intestine than by liver microsomes supporting the results obtained with recombinant UGTs. The most selective 4-dimethylaminophenyl and triazole C3 substituted 7-hydroxycoumarins could be very useful substrates in studying the function and expression of the human UGT1A10.

Keywords: 7-hydroxycoumarin derivative, UDP-glucuronosyltransferase, *in silico*, fluorescence, drug metabolism

Introduction

The extents of absorption and first-pass metabolism in the intestine and liver strongly affect the bioavailability of drugs and other orally ingested xenobiotic compounds¹⁻². Although hepatic metabolism is the major determinant of first-pass metabolism for most drugs, intestinal metabolism is critical for the bioavailability of certain compounds, particularly those that could be directly conjugated, like phenols and flavonoids³⁻⁵. Such xenobiotics typically contain a nucleophilic functional group, usually a hydroxyl group, that can accept an endogenous conjugating moiety, particularly glucuronic acid or sulfone. More rarely the conjugating group is methyl, acetyl or amino acid⁶.

The UDP-glucuronosyltransferase enzymes (UGTs, EC 2.4.1.17) catalyze about 35% of the drug conjugation reactions and are abundantly expressed among the intestinal conjugating enzymes^{4-5, 7}. They catalyze transfer of the glucuronic acid moiety from UDP-glucuronic acid cofactor onto hydroxyl, amine, carboxylic acid, thiol or thioacid groups of the aglycone substrates, reactions that are commonly called glucuronidation⁸. There is a significant difference in the expression profile of individual UGTs between the intestine and liver⁹⁻¹¹. While about ten different UGTs are abundantly expressed in the liver, only UGT1A1, UGT1A10, UGT2B7 and UGT2B17 are expressed in the small intestine to significant amounts at the protein level^{10, 12-14}. Unfortunately, the high activity and importance of the intestinal UGT1A10 was (and still is) often underestimated due to common use of poorly-active commercial UGT1A10¹³.

UGT1A10 glucuronidates many drugs and xenobiotics^{13, 15-17}. Glucuronidation of estriol at the 3-OH and of estrone could be used as selective reactions for UGT1A10, but their measurements require chromatographic separation of the resulting glucuronide from the substrate^{16, 18}. Likewise, dopamine is a UGT1A10 selective substrate, but its low affinity¹⁹

1
2
3 has limited its use to qualitative measurements only¹⁴. Accordingly, availability of more
4
5 convenient marker substrates for UGT1A10 would foster evaluation of glucuronidation
6
7 reactions, particularly if the assays were easy and fast to perform.
8
9

10 The interactions between substrates and xenobiotic metabolizing enzymes are increasingly
11
12 being studied by in silico modeling²⁰⁻²³. Currently, the lack of crystal structures of the N-
13
14 terminal domain of any mammalian UGT impedes structure-activity relationship and
15
16 mechanistic studies. UDP-glucuronic acid binds at the C-terminal domain, which is highly
17
18 homologous among different UGTs and evolutionary conserved. The structure of the latter
19
20 domain has been solved by X-ray crystallography²⁴. However, that available crystal structure
21
22 does not provide sufficient data to predict binding of acceptor substrates, e.g. a drug
23
24 molecule, as substrates bind to the N-terminal domain, which is more variable than the C-
25
26 terminal domain among UGT enzymes. In silico models for this domain were constructed
27
28 previously²⁰⁻²¹, but we need better ones in order to analyze substrate-enzyme interactions in
29
30 UGTs at the atomic level.
31
32

33
34 The hydroxyl group at C7 on the coumarin scaffold renders the compound fluorescent and
35
36 glucuronidation of this hydroxyl abolishes the fluorescence (Figure 1)²⁵. Substituents at
37
38 positions such as C3 or C4 of the coumarin do not quench the 7-hydroxycoumarin
39
40 derivatives' fluorescence, but modify its intensity, depending on the substituent's chemical
41
42 nature. The 7-hydroxyl group on coumarin is also a good functional group for
43
44 glucuronidation by many UGTs. Therefore, fluorescent 7-hydroxycoumarin derivatives
45
46 provide an opportunity to design novel fluorescent substrates for UGTs, using molecular
47
48 modelling as the starting point.
49
50

51
52 [Figure 1]
53
54
55
56
57
58
59
60

1
2
3 In this study, we first constructed homology models for all the human UGT enzymes of
4 subfamily 1A and used them to design fluorescent 7-hydroxycoumarin derivatives *in silico*.
5
6 We then synthesized six compounds and developed a convenient multiwell plate assay
7
8 protocol, based on fluorescence decrease, to test their glucuronidation rate. The results led to
9
10 the identification of several 3-substituted 7-hydroxycoumarins as selective substrates for the
11
12 human UGT1A10. A UGT1A10 mutant was prepared based on the model and as a test for it.
13
14 Subsequently, glucuronidation kinetic analyses of the 3-substituted 7-hydroxycoumarins, by
15
16 wild-type and mutant UGT1A10, were carried out using the same multiwell plate assay
17
18 protocol.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Experimental section

Materials: Alamethicin, trichloroacetic acid, UDPGA sodium salt, 7-hydroxycoumarin (99%), 7-hydroxy-(4-trifluoromethyl)coumarin (99%) and bovine serum albumin were from Sigma-Aldrich (Mannheim, Germany). Formic acid (99 %) and MgCl₂ were from Riedel-de Haen (Vantaa, Finland). Acetonitrile (Ultra gradient HPLC grade), methanol (HPLC gradient grade) and glycine were from J.T. Baker (Deventer, the Netherlands). Ethanol (≥99.5 %, Etax Aa) was from Altia (Helsinki, Finland). Water was deionized by MilliQ gradient A10.

Methods

Modeling. To enable structure-based design of UGT1A10 selective substrates, all nine UGT1A-enzymes were modeled. Sequences of human UGT1A enzymes were gathered from the UniProt Knowledgebase at www.uniprot.org (UniProt Consortium, 2015). The accession codes for the retrieved UGT1As were: Q9HAW8 (1A10), O60656 (1A9), Q9HAW9 (1A8), Q9HAW7 (1A7), P19224 (1A6), P35504 (1A5), P22310 (1A4), P35503 (1A3) and P22039 (1A1). To identify template protein structures for homology modeling purposes, the retrieved UGT sequences were used in blast searches against the protein data bank (PDB) structures. Based on the results of these searches, structures 2O6L²⁴, 3HBF²⁶, 3WC4²⁷ and 2C1Z²⁸ were selected as templates for homology modeling. The sequence alignment for the modeling was produced in two steps. First a protein structure-based sequence alignment was derived for the selected four protein structures by using Vertaa in Bodil²⁹ and the 2C1Z-structure as a template, since it gave the best match for UGT1A10 and contained both the N- and C-termini. In the second step the above listed nine UGT1A sequences were aligned, using Bodil, against the structural alignment, using STRMAT110 matrix³⁰ with 40 as the gap penalty. The alignment was adjusted for occasional variations in sequence length and used to


1
2
3 create models for each UGT1A, as well as in model construction that was performed using
4
5 Modeller version 9.15³¹.

6
7
8 **Molecular docking.** The ligands that were selected for docking studies were prepared by
9
10 using LigPrep (version 3.3, Schrödinger, LLC, New York, NY, 2015). The shapes and
11
12 electrostatic properties of the substrate binding sites of modeling-produced UGT1A enzymes
13
14 were analysed with Panther³² and molecular docking was performed with PLANTS³³.

15
16
17 **Synthesis.** All the synthesis reactions were carried out using commercial materials and
18
19 reagents without further purification, unless otherwise noted. Reaction mixtures were heated
20
21 using the CEM Discovery microwave apparatus. All reactions were monitored by thin layer
22
23 chromatography (TLC) on silica gel plates. ¹H NMR and ¹³C NMR data were recorded on a
24
25 Bruker Avance 400 MHz spectrometer or Bruker Avance III 300 MHz spectrometer.
26
27 Chemical shifts are expressed in parts per million values (ppm) and are designated as s
28
29 (singlet), br s (broad singlet), d (doublet), dd (double doublet), t (triplet). Coupling constants
30
31 (*J*) are expressed as values in hertz (Hz). The mass spectra were recorded using Micromass
32
33 LCT ESI-TOF equipment. Elemental analyses were done with Elementar Vario EL III
34
35 elemental analyzer. All compounds tested present more than 95 % purity.

36 37 38 39 40 **General procedure for the synthesis of coumarin derivatives**

41
42
43 The coumarin derivatives 1-6 were synthesized using Perkin-Oglialor condensation reaction
44
45 (Scheme 1). The method was developed from the earlier published procedures and transferred
46
47 to a microwave reactor.³⁴



1
2
3 Scheme 1. The general procedure for the synthesis of coumarin derivatives

4
5
6 A typical procedure: a mixture of salicylaldehyde derivative (2 mmol) and phenyl acetic acid
7
8 derivative (2.1 mmol), acetic acid anhydride (0.6 ml) and triethylamine (0.36 ml) were placed
9
10 in a microwave reactor tube and heated at 100-170 °C in the microwave apparatus for 10-20
11
12 min. After cooling, 2 ml of 10% NaHCO₃ solution was added and the precipitate was filtered,
13
14 dried and recrystallized from EtOH/H₂O or acetone/H₂O mixture. The acetyl group(s) were
15
16 removed by treating the compound with MeOH/NaOH(aq) solution for 30-60 min at r.t. The
17
18 solution was acidified with HCl (aq.) and the precipitate was filtered and recrystallized if
19
20 needed. Experimental data for 7-acetoxy-3-(4-fluorophenyl)-2*H*-chromen-2one, 7-hydroxy-3-
21
22 (4-fluorophenyl)-2*H*-chromen-2-one (**1**), 7-acetoxy-3-(4-acetoxyphenyl)-2*H*-chromen-2one,
23
24 7-hydroxy-3-(4-hydroxyphenyl)-2*H*-chromen-2one (**2**), and 7-acetoxy-3-(4-
25
26 methoxyphenyl)coumarin, 7-hydroxy-3-(4-methoxyphenyl)coumarin (**3**) were already
27
28 published elsewhere.³⁴

29
30
31
32 7-hydroxy-3-(4-(dimethylamino)phenyl)-2*H*-chromen-2-one (**4**)³⁵

33
34
35 In the first step 7-acetoxy-3-(4-(dimethylamino)phenyl)-2*H*-chromen-2one was obtained.

36
37
38 Yield: 70%; ¹H-NMR (400 MHz, d⁶-DMSO) δ: 2.31 (s, 3H, CH₃CO), 2.95 (s, 6H, (CH₃)₂N-),
39
40 6.77 (d, *J*³ = 9.0 Hz, 2H, H-2', H-6'), 7.14 (dd, *J*³ = 8.4 Hz, *J*⁴ = 2.2 Hz, 1H, H-5), 7.26 (d,
41
42 *J*⁴ = 2.2 Hz, 1H, H-8), 7.63 (d, *J*³ = 9.0 Hz, 2H, H-3', H-5') 7.76 (d, *J*³ = 8.5 Hz, 1H, H-5),
43
44 8.11 (s, 1H, H-4); ¹³C-NMR (100.6 MHz, d⁶-DMSO) δ: 20.85, 39.84, 109.44, 111.58, 117.76,
45
46 118.57, 121.57, 126.00, 128.82, 129.11, 136.46, 150.45, 151.90, 152.77, 159.74, 168.85.

47
48
49 In the second step 7-hydroxy-3-(4-(dimethylamino)phenyl)-2*H*-chromen-2one (**4**) was
50
51
52 obtained.

1
2
3 Yield: 85% yellow solid; $^1\text{H-NMR}$ (400 MHz, $\text{d}^6\text{-DMSO}$) δ : 2.94 (s, 6H, $(\text{CH}_3)_2\text{N-}$), 6.72 (d,
4 $J^4 = 2.3$ Hz, 1H, H-8), 6.75 (d, $J^3 = 9.0$ Hz, 2H, H-2', H-6'), 6.79 (dd, $J^3 = 8.4$ Hz, $J^4 = 2.3$
5 Hz, 1H, H-5), 7.55 (d, $J^3 = 8.5$ Hz, 1H, H-5), 7.58 (d, $J^3 = 9.0$ Hz, 2H, H-3', H-5'), 7.99 (s,
6 1H, H-4); $^{13}\text{C-NMR}$ (100.6 MHz, $\text{d}^6\text{-DMSO}$) δ : 39.92, 101.59, 112.33, 113.16, 122.30,
7 122.32, 129.34, 137.83, 150.07, 154.27, 160.30, 160.41. ESI-MS: m/z (rel. abund. %) 304 (M
8 + Na^+); elemental anal. for $\text{C}_{17}\text{H}_{15}\text{N}_1\text{O}_3$, calc. C% 72.58, H% 5.37, N% 4.98, found C%
9 72.45, H% 5.40, N% 5.15.
10
11
12
13
14
15
16
17

18 7-hydroxy-3-(*p*-tolyl)-2H-chromen-2-one (**5**)³⁶
19
20
21

22 In the first step 7-acetoxy-3(*p*-tolyl)-2H-chromen-2one was obtained.
23

24 Yield: 70%; $^1\text{H-NMR}$ (300 MHz, $\text{d}^6\text{-DMSO}$) δ : 2.32 (s, 3H, CH_3CO), 2.35 (s, 3H, $\text{CH}_3\text{-Ph}$),
25 7.17 (dd, $J^3 = 8.4$ Hz, $J^4 = 2.2$ Hz 1H, H-6), 7.27 (d, $J^3 = 8.0$ Hz, 2H, H-2', H-6'), 7.29 (d, J^4
26 = 2.2 Hz, 1H, H-8), 7.63 (d, $J^3 = 8.2$ Hz, 2H, H-3', H-5') 7.80 (d, $J^3 = 8.5$ Hz, 1H, H-5), 8.21
27 (s, 1H, H-4); $^{13}\text{C-NMR}$ (100.6 MHz, $\text{d}^6\text{-DMSO}$) δ : 20.77, 20.82, 109.56, 117.37, 118.66,
28 125.99, 128.25, 128.76, 129.30, 131.60, 138.09, 139.37, 152.51, 153.28, 159.47, 168.74.
29
30
31
32
33
34
35

36 In the second step 7-hydroxy-3(*p*-tolyl)-2H-chromen-2one (**5**) was obtained
37
38

39 Yield: 85% brownish solid; $^1\text{H-NMR}$ (300 MHz, $\text{d}^6\text{-DMSO}$) δ : $^{13}\text{C-NMR}$ (75 MHz, $\text{d}^6\text{-}$
40 DMSO) δ : 20.74, 101.65, 112.01, 113.30, 122.07, 128.04, 128.69, 129.80, 132.14, 137.37,
41 140.38, 154.77, 160.05, 161.05. ESI-MS: m/z (rel. abund. %) 275 (M + Na^+); elemental anal.
42 for $\text{C}_{16}\text{H}_{12}\text{O}_3$, calc. C% 76.18, H% 4.79, found C% 75.95, H% 4.83.
43
44
45
46
47

48 7-hydroxy-3-(1H-1,2,4-triazol-1-yl)-2H-chromen-2-one (**6**)
49
50

51 In the first step 2-oxo-3-(1H-1,2,4-triazol-1-yl)-2H-chromen-7-yl acetate was obtained.
52
53
54
55
56
57
58
59
60

1
2
3 Yield: 65% slightly brown solid; ¹H-NMR (400 MHz, d₆-DMSO) δ: 2.33 (s, 3H, CH₃-CO),
4
5 7.27 (dd, J₃ = 8.5 Hz, J₄ = 2.2 Hz, 1H, H-6), 7.44 (d, J₄ = 2.2 Hz 1H, H-8), 7.98 (d, J₃ =8.5
6
7 Hz, 1H, H-5), 8.33 (s, 1H, H-3'), 8.61 (s, 1H, H-4), 9.20 (s, 1H, H-5'); ¹³C-NMR (100.6
8
9 MHz, d₆-DMSO) δ: 20.87, 110.02, 116.19, 119.50, 123.04, 130.10, 131.81, 144.40, 152.06,
10
11 152.21, 153.12, 155.73, 168.76. FT-IR (KBr, cm⁻¹): 3416, 1723, 1617, 1208, 1129. mp. 190–
12
13 192 °C. ESI-MS: m/z (rel. abund. %): calculated for (M + Na⁺)=294.0485, measured
14
15 294.0499, Δ=-1.4 mDa
16
17

18
19 In the second step the acetyl group was removed by treating the above mentioned compound
20
21 with MeOH/K₂CO₃ solution.
22
23

24 Yield: 92 % slightly brown solid; ¹H-NMR (400 MHz, d₆-DMSO) δ: 6.85 (d, J₄ = 2.3 Hz,
25
26 1H, H-8), 6.90 (dd, J₃ = 8.5 Hz, J₄ = 2.3 Hz, 1H, H-6), 7.74 (d, J₃ = 8.6 Hz, 1H, H-5), 8.27
27
28 (s, 1H, H-3'), 8.49 (s, 1H, H-4), 9.10 (s, 1H, H-5'), 10.83 (br s, 1H, OH). ¹³C-NMR (100.6
29
30 MHz, d₆-DMSO) δ: 102.07, 110.42, 114.23, 119.72, 130.70, 134.11, 144.24, 151.78, 153.96,
31
32 156.37, 162.01. FT-IR (ATR, cm⁻¹): 1724, 1623, 1511, 1328, 1129 811. mp. decomp. > 312
33
34 °C. ESI-MS: m/z (rel. abund. %): calculated for (M - H⁺)=228.0415, measured 228.0408,
35
36 Δ=0.7 mDa
37
38

39
40 **UGTs and microsomes.** Recombinant human UGTs 1A1, 1A3, 1A6, 1A7, 1A8, 1A9, 1A10,
41
42 2A1, 2A2, 2A3, 2B4, 2B10, 2B7, and 2B17 were produced, as His-tagged proteins, in
43
44 baculovirus-infected insect cells as previously described³⁷⁻³⁹. The relative expression level of
45
46 each of these recombinant UGTs was evaluated by immunodetection, using monoclonal
47
48 antibody against the His-tag, as described elsewhere⁴⁰. A numeric value of 1.0 was given to
49
50 the expression level of UGT1A8 and the relative expression level of each of the other UGTs
51
52 was related to this value. Normalized activities were obtained by dividing the glucuronidation
53
54 rate values by the relative expression level of the tested UGT. In addition, UGTs 1A4, 2B10
55
56
57
58
59
60

1
2
3 and 2B15 were purchased from Corning Life Sciences (New York, USA) and are marked, in
4
5 Figure 5, with a “C” to indicate that they are commercial enzymes. The expression levels of
6
7 the UGTs in the commercial samples could not be determined, so their protein concentration
8
9 was used to calculate the reaction rate.
10

11
12 A commercial HLM pool (cat no:452210, BD Gentest, Bedford, MA, USA) and human
13
14 intestine microsomes (HIM) pool (lot. no 1110189, XenoTech, Kansas City, KS, USA) were
15
16 purchased. Pig liver samples were prepared from untreated female pigs that were used for
17
18 practicing surgical procedures at the University of Kuopio (currently: University of Eastern
19
20 Finland, Kuopio campus). Other animal liver microsomes were prepared as described
21
22 previously⁴¹. The Ethics Committee for Animal Experiments, University of Kuopio approved
23
24 these experiments.
25
26

27 28 **Mutagenesis of UGT1A10**

29
30
31 The UGT1A10 mutant 1A10-H210M was prepared according to the QuikChange
32
33 methodology, using the cloned UGT1A10 in pFastBac⁴² as a template and the following two
34
35 oligonucleotides:
36
37

- 38 1. 5'-ACTTTCAAGGAGAGAGTATGGAACATGATCGTGCACTTGGAGGACCATTT-3'
- 39
40
- 41 2. 5'- AAATGGTCCTCCAAGTGCACGATCATGTTCCATACTCTCTCCTTGAAAGT-3'
- 42
43

44 The entire coding sequence of UGT1A10 in the mutant clone was sequenced and,
45
46 subsequently, recombinant baculovirus was prepared and used to express the mutant enzyme
47
48 in baculovirus-infected SF9 insect cells.
49
50

51 **Absorbance and fluorescence spectra of C3 substituted 7-coumarins**

52
53
54
55
56
57
58
59
60

1
2
3 The absorbance spectra of 10 μM coumarin derivatives at 100 mM Tris-HCl pH 7.4
4 containing 10 % dimethylsulfoxide were measured using a Hitachi U-2000
5 Spectrophotometer (Tokyo, Japan). Excitation and emission fluorescence spectra of 0.1 μM
6 coumarin derivatives in 100 mM Tris-HCl pH 7.4 were measured using a Shimadzu RF-5000
7 spectrophotofluorometer (Tokyo, Japan). The excitation spectra was from 200 to 420 nm at
8 460 nm emission and the emission spectra was from 400 to 600 nm at 390 nm excitation
9 (Data in supplementary Table S1 and Figures S1 and S2). The effect of pH on fluorescence
10 intensity was determined at 405 nm excitation and 460 nm emission, in the presence of either
11 1.5 % trichloroacetic acid, 100 mM phosphate buffers at pH 5, 6, 7, 8 and 9, or 1.6 M
12 glycine-NaOH pH 10.4.
13
14
15
16
17
18
19
20
21
22
23

24 25 **Glucuronidation reactions**

26
27
28 The incubation mixtures for glucuronidation assays contained 100 mM Tris-HCl buffer pH
29 7.4, 2.5 mM MgCl_2 , 0.5 mM UDPGA, recombinant UGT or microsomes as the enzyme
30 source and 0 – 15 μM of the test aglycone substrate. When the incubation mixtures contained
31 microsomes, alamethicin was used at a final concentration of 12.5 $\mu\text{g/ml}$, but it was not
32 included in the recombinant enzyme assays⁴³. In the first experiments three negative control
33 samples were tested, namely i) without the substrate 7-hydroxycoumarin derivative, ii)
34 without the cofactor UDPGA, or iii) without the enzyme source. In subsequent experiments,
35 the control samples lacked the enzyme source since it gave the highest fluorescence
36 background. Preliminary experiments were done under different conditions than most of the
37 later assays, namely in 2.5 ml of 100 mM phosphate buffer pH 7.4, containing 500 μg pig
38 liver microsomes, 1.0 μM compound **6** and 0.5 mM UDPGA, at room temperature.
39 Fluorescence spectra (excitation 200 - 420 nm; emission 400 – 600 nm) or fluorescence
40 decrease at 390 nm excitation and 460 nm emission, were measured in these preliminary
41 experiments, using a Shimadzu RF-5000 spectrophotofluorometer.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Most of the glucuronidation assays were carried out in 96 multiwell plate format, and
4 incubations were carried out in 100 μ l and at 37°C, in the presence of Tris-HCl buffer pH 7.4,
5 UDPGA and the tested 7-hydroxycoumarin derivative, at the indicated concentrations.
6
7 Fluorescence decline in the multiwell plate experiments was monitored every other minute,
8
9 for 40 min, using an excitation filter at 405 nm and detection at 460 nm, in a Victor2 1420
10
11 Multilabel counter (PerkinElmer, Life Sciences, Turku, Finland). The fluorescence values
12
13 were transformed into molarity using the aglycone substrates for making the respective
14
15 standard curves. Slopes of the substrate concentration decrease per minute were calculated
16
17 using linear regression analysis, in which the linear part of the kinetic assay indicated the
18
19 glucuronidation rate. Enzyme catalyzed glucuronidation rate was calculated by subtracting
20
21 the blank value from the full reaction value. The intra-assay variability of the kinetic assays
22
23 was 6 % when compound **6** was used as the aglycone substrate. Kinetic analyses were also
24
25 performed in the same 96 multiwell plates format, with excitation filter at 405 nm and
26
27 detection at 460 nm, using 6-8 different substrate concentrations per substrate and two
28
29 different protein concentrations for both the wild-type and mutant UGT1A10. The higher
30
31 concentrations, 13.5 mg/L for UGT1A10 and 12.0 mg/L for the UGT1A10 mutant, were used
32
33 when the substrates were HFC, compounds **4** and **6**, whereas the lower protein
34
35 concentrations, 6.75 and 6.0 mg/L for UGT1A10 and the mutant, respectively, were used
36
37 when the substrates were compounds **1**, **2**, **3**, and **5**.

38
39 In end-point determinations, the glucuronidation reactions were stopped by the addition of
40
41 150 μ l 1.6 M glycine-NaOH buffer, pH 10.4, followed by fluorescence measurements at 405
42
43 nm excitation and 460 nm emission. There was a good correlation between kinetic and end-
44
45 point assays (data not shown).
46
47
48
49
50
51
52

53
54 **HPLC-MS analysis of 7-hydroxy-3-triazolecoumarin glucuronide.** For further analysis of
55
56 7-hydroxy-3-triazolecoumarin glucuronide, 10 μ M of compound **6** were incubated in 100 μ l
57
58
59
60

1
2
3 of 100 mM Tris-HCl pH 7.4 buffer containing 5 mM MgCl₂, 1 mM UDPGA and either 30 -
4
5 40 µg recombinant UGT, 30 µg HLM or 20 µg HIM, for 1 h at 37 C. The reactions were
6
7 stopped by the addition of 300 µl methanol, centrifugation and then the supernatant was
8
9 divided into two. One part, 100 µl supernatant, was mixed with 150 µl 1.6 M glycine-NaOH
10
11 pH 10.4 and subjected to fluorescence measurements as described above for the 96-well
12
13 plate. The other part, 250 µl supernatant, was stored at – 20 C until analysis by HPLC-MS.
14
15

16
17 An Agilent 1200 Series Rapid Resolution LC System (Agilent Technologies, Waldbronn,
18
19 Germany) was used for the chromatographic separation, equipped with a reversed-phase C8
20
21 column (Brownlee Supra, 3 µm, 50 × 2.1 mm, Perkin Elmer). The mobile phases were (A)
22
23 0.1% aqueous formic acid and (B) acetonitrile. A linear gradient from 10% to 90% B in five
24
25 min was applied, followed by one min isocratic elution with 90% B and column re-
26
27 equilibration, yielding a total analysis time of nine min. The flow rate was 0.3 mL/min,
28
29 injection volume 3 µL and column oven temperature 30 °C. For the MS detection, a Finnigan
30
31 LTQ ion trap mass spectrometer (Thermo, San Jose, CA) was used in the positive
32
33 electrospray (ESI) mode. A divert valve was used to direct eluent flow to the waste for 1 min
34
35 at the beginning and at the end of the gradient run. The MS analysis was carried out using the
36
37 following parameters: spray voltage 4 kV, sheath gas 30 (instrument units), aux gas 15,
38
39 sweep gas 3, capillary temperature 250 °C, capillary voltage 43 V, tube lens 100 V. The
40
41 collision energy used for MS/MS was 30 V. The acquired full scan MS range was m/z 60 –
42
43 600. Ions used for the detection of the aglycone and glucuronide conjugate were m/z 230
44
45 [M+H]⁺ and m/z 406 [M+H+176]⁺, respectively. Data was acquired and processed using
46
47 Xcalibur software package.
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Modeling UGT1A enzymes

Template structures for homology modeling of the UGT enzymes of subfamily 1A were selected based on sequence similarity, using the blast option in Uniprot. Structures that contained both the sugar-nucleotide cofactor and a small aglycone molecule were beneficial for the model and, therefore, structures (pdb-codes) 2C1Z/X, 2O6L, 3HBF, and 3WC4 were selected. The conserved lipophilic region that spans the endoplasmic reticulum membrane and ends in the “cytoplasmic tail” were excluded from the model because the focus of the model construction was on the catalytic site and its surrounding area. In addition, other structures outside the catalytic site of the model, including loops and amino acid side chain conformations, were not optimized. Optimizing efforts were considered detrimental for the quality of the models as the sequence similarity between the templates and the UGT sequences was very low. In other words, the models were not considered to be good enough for molecular dynamics simulations in order to evaluate binding energy or other kinetic parameters. On the other hand, an essential part of the model building was to predict binding of the 7-hydroxycoumarin derivatives so that glucuronidation will occur at the 7-hydroxyl group and for this purpose the models were adequate.

The homology models were used to design novel and UGT-selective fluorescent 7-hydroxycoumarin substrate molecules, whose fluorescence will decrease upon glucuronidation (Figure 1). Docking of the 7-hydroxycoumarin scaffolds (Figure 2A-C) into different UGT1A models yielded several possible conformations. One of them oriented the 7-hydroxy group toward the bound UDP-glucuronic acid (UDPGA) cofactor at the catalytic site and, simultaneously, the coumarin core was optimally placed into a nearby cavity in the catalytic site (Figure 2D). In our models, the coumarin scaffold could be stabilized through its

1
2
3 C2-carbonyl oxygen, accepting a hydrogen bond from Q101 in UGT1A8 (Figure 2C),
4 UGT1A9 and UGT1A10 (Figure 2A). Even stronger stabilizing interactions could be formed
5
6 between the coumarin carbonyl at C2 and R102 of UGT1A6 (Figure 2C). On the other hand,
7
8 D103 in UGT1A1 (Figure 2B), E104 in UGT1A3 and UGT1A4, or P101 in UGT1A7, are not
9
10 capable of forming similar stabilizing hydrogen bond interactions at this site, suggesting that
11
12 the coumarin core would not be an optimal substrate for these UGTs. Furthermore, R103 of
13
14 UGT1A7, UGT1A8 and UGT1A9, counteracted the stabilizing interactions and partially
15
16 blocked the binding of the coumarin scaffold to these UGTs due to its size (Figure 2C).
17
18 Unlike significantly bulkier R103 of UGT1A8 (Figure 2C), the Q103 of UGT1A10 at this
19
20 site could donate a hydrogen bond to the oxygen at position 1 of the coumarin scaffold
21
22 (Figure 2A).
23
24
25

26
27 [Figure 2]
28
29

30 Based on these homology models, there was an additional, but variable in size, free space
31
32 available in the active site of each UGT1A enzyme, next to position 3 of the coumarin core.
33
34 When combined with the 7-hydroxycoumarin docking site analyses (see above), this
35
36 additional space was large enough in UGT1A1 and UGT1A10 to accommodate five- or six-
37
38 membered ring substituents (Figure 2D). In contrast, a bulkier phenylalanine (F212) is
39
40 present in the UGT1A6 model at this position, clearly hindering binding of any 3-substituted
41
42 7-hydroxycoumarins. The properties of this binding site were quite different also between
43
44 UGT1A1 and UGT1A10. While UGT1A1 has a hydrophobic methionine (M213) facing this
45
46 site (Figure 2B), UGT1A10 has a histidine at the corresponding site (H210; Figure 2A). On
47
48 the opposite side of this additional space, UGT1A10 has an alanine (A100), while UGT1A1
49
50 has an asparagine (N102) aligned to the same position. This may mean that in UGT1A10
51
52 there is enough space for rather large 3-substituted 7-hydroxycoumarins, whereas UGT1A1
53
54 would have problems accommodating larger substitutions at this position of the 7-
55
56
57
58
59
60

1
2
3 hydroxycoumarin scaffold. At the other end of the UGT1As “spectrum”, UGT1A6 has a
4
5 glutamic acid (E101) aligned at the same site, which would limit the cavity even further.
6
7

8 Based on docking of a virtual library into the UGT1A10 model, the most promising
9
10 molecules were 7-hydroxycoumarin derivatives with the following substituents at the C3
11
12 position: 4-fluorophenyl (1), 4-hydroxyphenyl (2), 4-methoxyphenyl (3), 4-
13
14 dimethylaminophenyl (4), 4-methylphenyl (5) or triazole (6). Among these, the triazole (6)
15
16 derivative could be stabilized by H210 in UGT1A10, while the corresponding methionine in
17
18 UGT1A1 (M213) would not be able to form hydrogen bonds with it. In contrast, the addition
19
20 of a phenyl moiety to the C3-position would allow binding by both UGT1A1 and UGT1A10,
21
22 as the hydrophobic methionine in UGT1A1 is quite an ideal companion, while the histidine in
23
24 UGT1A10 could change its conformation according to the donor functionality, as with
25
26 triazole. Based on these observations and considerations, the six new coumarin derivatives
27
28 were designed and synthesized (Figure 3: compounds 1-6). The selected compounds were
29
30 made from inexpensive starting materials, producing 3-substituted coumarins with 5- or 6-
31
32 membered rings.
33
34
35

36
37 [Figure 3]
38
39

40 **Glucuronidation of the 3-substituted 7-hydroxycoumarins**

41
42 The absorbance and fluorescence spectra of compounds 1 – 6 were very similar showing,
43
44 however, some differences in intensity as well as excitation and emission peaks among them
45
46 (Figure 4A, Supplementary Figures 1 and 2, Supplementary Table 1.). The fluorescence was
47
48 pH dependent, emitting strongly in neutral and alkaline solutions.
49
50

51
52 In the first glucuronidation experiments, the fluorescence intensity of all the C3 substituted 7-
53
54 hydroxycoumarin derivatives, compounds 1 – 6, decreased when they were incubated in the
55
56
57
58
59
60

1
2
3 presence of pig liver microsomes and UDPGA, in a buffer containing 100 mM Tris-HCl pH
4 7.4 and 5 mM MgCl₂ (Figure 4B). No significant fluorescence decrease was observed in the
5 negative controls, namely in the absence of either microsomes, a coumarin derivative such as
6 **6**, or UDPGA. The fluorescence changes were linearly dependent on the amount of
7 microsomes (Figure 4C), indicating that the biosynthesis of C3 substituted 7-
8 hydroxycoumarin derivatives to nonfluorescent glucuronide conjugates was catalyzed by one
9 or more UDP-glucuronosyltransferase enzymes in the microsomes. The presence of
10 alamethicin increased glucuronidation rates in this microsomal sample, whereas the addition
11 of more than 5 % (v/v) dimethyl sulfoxide, acetonitrile or ethanol decreased it (Figure 4D).
12 An example for glucuronide formation under such incubation condition, using **6** as the
13 substrate, is presented in Figure S3.
14
15
16
17
18
19
20
21
22
23
24
25
26

27 [Figure 4]

28
29
30 The above results with **6** and pig liver microsomes suggested that the glucuronidation rates of
31 the new 7-hydroxycoumarin derivatives could be accurately determined under our
32 standardized assay conditions, using different enzyme sources. Subsequently, the
33 glucuronidation rates of all the new C3 substituted 7-hydroxycoumarin derivatives by nearly
34 all the human UGTs, including enzymes that are not commercially available, were
35 determined (Figure 5). For comparison and additional controls, the glucuronidation of 7-
36 hydroxycoumarin and 4-trifluoromethyl-7-hydroxycoumarin (HFC), that carry no C3
37 substitution, by the recombinant enzymes were also measured (Figure 5).
38
39
40
41
42
43
44
45
46
47

48 [Figure 5]

49
50
51 The human UGTs screen revealed that all six newly synthesized C3 substituted 7-
52 hydroxycoumarins were glucuronidated by UGT1A10 more rapidly than by other UGT
53 forms. Furthermore, **2**, **4**, **5** and **6** were selective for UGT1A10, as other UGTs catalyzed their
54
55
56
57
58
59
60

1
2
3 glucuronidation at very low rates. The remaining two new substrates, **1** and **3**, were
4
5 glucuronidated, in addition to UGT1A10, also by UGT1A1, at rates of about 40 % and 20 %,
6
7 respectively, of the corresponding UGT1A10 rate (Figure 5). The glucuronidation profiles of
8
9 the new derivatives differed significantly from the control substrates, 7-hydroxycoumarin and
10
11 HFC, which were glucuronidated primarily by UGT1A6 (7-hydroxycoumarin), or UGT1A6
12
13 and UGT1A10 (HFC), as well as by few other UGTs at lower rates (Figure 5).
14

15
16 In addition to recombinant UGTs, the glucuronidation rates of all the new C3 7-
17
18 hydroxycoumarin derivatives, along with 7-hydroxycoumarin and HFC, were measured in
19
20 human liver microsomes (HLM) and human intestinal microsomes (HIM). The results
21
22 showed that all the new compounds were glucuronidated by HIM at higher rates than by
23
24 HLM (Figure 6). Furthermore, **2**, **4** and **6** were not glucuronidated by HLM at all, or only at
25
26 very low rates, whereas **3** and **5** were conjugated by HLM to about 20 – 25% of the rate
27
28 exhibited by HIM. **1** was glucuronidated by HLM at about 40% of the corresponding rate in
29
30 HIM (Figure 6). Kinetics of compound **6** glucuronidation confirmed that glucuronidation is
31
32 more specific in intestinal than hepatic microsomes, as its K_m -value was 82 (49-115) μM and
33
34 V_{max} 4.0 (2.6-5.4) $\mu\text{mol}/(\text{min} * \text{g prot})$ in human hepatic microsomes and its K_m -value was 12
35
36 (8.8-15) μM and V_{max} 3.5 (2.9-4.0) $\mu\text{mol}/(\text{min} * \text{g prot})$ in human intestinal microsomes.
37
38 Adding albumin to incubation mixture increased both K_m - and V_{max} -values in intestinal
39
40 microsomes. In sharp contrast to glucuronidation of the new 7-hydroxycoumarin derivatives,
41
42 the “parent compound” 7-hydroxycoumarin, as well as HFC, were glucuronidated to much
43
44 higher rates by HLM than by HIM (Figure 6).
45
46
47
48

49
50 [Figure 6]
51

52 53 **Effect of H210 to M210 mutation on UGT1A10 activity** 54 55 56 57 58 59 60

1
2
3 The developed model, by being explicit about the role of certain key UGT1A10 residues in
4 the binding of the designed 7-hydroxycoumarin derivatives, also allowed testing it by
5 mutagenesis. Hence, we prepared mutant 1A10-H210M, a mutant of UGT1A10 in which
6 H210 was changed to methionine, the corresponding residue in UGT1A1. The mutant was
7 expressed in insect cells, similarly to all the other recombinant UGTs that were used in this
8 study, and its activity toward the new 7-hydroxycoumarin derivatives was tested. This was
9 combined with kinetic analyses of the glucuronidation of these compounds by both
10 UGT1A10 and UGT1A10-H201M, side-by-side (Fig. 7 and Table 1). The results
11 demonstrated clear effects of the mutation on the glucuronidation kinetics of most
12 compounds. A decrease of V_{\max} occurred in all but **2** and **6**, in which the K_m values were
13 considerably increased (Table 1). Changes in the K_m values of the other compounds were
14 variable, however, an increase in the case of HFC, no change for **5** and a decrease in **1**, **3** and
15 **4** (Table 1).
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 [Table 1.]
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

In this study we constructed predictive homology models for the human UGT1A enzymes in order to design selective substrates for them. The models indicated several key characteristics that differ among the active sites of individual UGT1A enzymes. These differences were exploited for the design and synthesis of six new 3-substituted 7-hydroxycoumarin derivatives. All the new compounds were good substrates for UGT1A10 and four of them, namely **2**, **4**, **5** and **6**, were selective substrates for this UGT (Fig. 5). Among the clear advantages of these new 7-hydroxycoumarin derivatives as UGT1A10 substrates are their extensive fluorescence and simple synthesis from low-cost starting materials that make them suitable for quick and convenient activity measurements in a high throughput format.

Currently, no high-resolution, or even low-resolution, structure of a full-length UGT is available from X-ray crystallography or cryo-electron microscopy. Although their 3D-model construction is challenging, homology models of UGT1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9 and 1A10 were constructed in this study. These models suggested that the active site of UGT1A10 is sufficiently different from the other UGTs to enable design and synthesis of selective substrates for it.

We had two goals in designing these substrates: they should be selective for UGT1A10 and determination of their glucuronidation should be based on easily measurable fluorescence change during the assay. As a starting point, the 7-hydroxycoumarin scaffold was selected, since it is a common UGT substrate and its derivatives have intense fluorescence⁴⁴. In addition, 7-hydroxycoumarin and 7-hydroxy-4-trifluoromethylcoumarin have both been shown to be glucuronidated by several different UGTs²⁵. The hydroxyl group of 7-hydroxycoumarin was oriented toward the UDPGA in the active site of the UGT1A10 model, indicating that there is space in the active site for an additional six or five ring substituent at

1
2
3 position C3 of the 7-hydroxycoumarin scaffold (Figure 2). Thus, we synthesized six new
4
5 UGT1A10 substrates, all of which were 7-hydroxycoumarin derivatives with various
6
7 substituents at position C3 of the coumarin scaffold.
8
9

10 All the new 7-hydroxycoumarin derivatives are highly fluorescent and their fluorescence
11
12 decreases upon enzymatic glucuronidation (see Figure 4 for an example with compound **6**).
13

14 A concern in these assays was non-linearity of the fluorescence at substrate concentrations
15
16 above 20 μM . However, fluorescence changes of these substrates were selective, sensitive
17
18 and quantitative enough for measurements below this concentration limit, as the amount of
19
20 UGT1A10 enzyme could be adjusted to yield linear glucuronidation rates.
21
22

23 The selectivities of the 7-hydroxycoumarin derivatives for UGT1A10 differed substantially.
24
25 While some of them, such as **2**, **4** and **6**, were highly selective, others, like **1** and **3**, were also
26
27 glucuronidated by UGT1A1 at considerable rates (Figure 5). Previous studies have shown
28
29 that fluorescent derivatives of N-butyl-4-phenyl-1,8-naphthalimide are UGT1A1 selective
30
31 substrates ⁴⁵.
32
33

34
35 Since UGT1A10 is an extrahepatic enzyme expressed at high level in the intestine, ¹¹ the
36
37 results obtained with recombinant UGTs could be tested with HLM and HIM. Although these
38
39 microsomal preparations contain several different UGTs each, HLM lacks a functional
40
41 UGT1A10 while HIM contains it ¹¹. Indeed, the glucuronidation rates in HLM of **4** and **6**, as
42
43 well as **2**, were very low or below the detection limit. Glucuronidation of **1**, **3** and **5** took
44
45 place in HLM at rates up to 40% of the rates in HIM (Figure 6). These results also suggest
46
47 which of the new compounds would be most useful for studies on UGT1A10 activity in
48
49 samples from human tissues that express or may express this enzyme. The current results
50
51 point at **2**, **4** and **6** as good candidates, **2** due to the lack of detectable activity in HLM, **4**
52
53 based on the combination of high rate with high selectivity, and **6** due to its high selective
54
55
56
57
58
59
60

1
2
3 fluorescence intensity (Figure 6 and supplementary Figures S1 and S2). It may be added here
4 that we recently reported that the commonly used commercial UGT1A10 has low activity¹³.
5
6
7 In this study we have used the UGT1A10-H preparation, not the commercial UGT1A10.
8
9
10 Researches should not expect to get similar results to those reported here for UGT1A10 when
11 working with the commonly used commercial UGT1A10. On the other hand, experiments
12 with commercial HIM and HLM are expected to reproduce the current results.
13
14

15
16 It is interesting to understand why **6** has a remarkably lower (less than 30 %) intrinsic
17 glucuronidation clearance (V_{\max}/K_m) by UGT1A10 than the other new 7-hydroxycoumarin
18 derivatives, **1 – 5** (Table 1). Examination of the substituents at C3 suggests that **6** with a
19 triazole derivative at C3 was glucuronidated less efficiently than derivatives containing
20 hydrophobic or other types of hydrophilic substituents. The reason for this could be that the
21 triazole causes stronger interactions than the other substituents in the active site of
22 UGT1A10, resulting in slower release of the formed glucuronide.
23
24
25
26
27
28
29
30

31
32 The present modeling work indicates specific residues that are expected to lead to substrate
33 selectivity of UGT1A10. We have tested one of the predicted residues, H210, by changing it
34 to M210, the corresponding residue in UGT1A1, expressed the mutant UGT1A10-M210 and
35 studied the glucuronidation kinetics of all the new compounds by both the wildtype (i.e.
36 UGT1A10-H210) and mutant enzymes. The results revealed changes in the K_m and/or V_{\max}
37 values of the glucuronidation kinetics of all the compounds, but with clear differences among
38 them (Figure 7 and Table 1). Another unexpected observation was the effect of the mutation
39 on HFC glucuronidation rate, which may suggest that the effect of the mutation is larger than
40 expected by the model, or that substrate(s) binding by UGT1A10 (also) involves an induced
41 fit mechanism.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In conclusion, in this study 3D molecular models of the UGT1As were constructed and used
4 for the design and synthesis of six new fluorescent UGT substrates. A new multiwell-based
5 method that takes advantage of the fluorescence of the compounds and their fluorescence
6 decrease upon glucuronidation, was established to measure glucuronidation rates. Of the new
7 compounds, 4-dimethylaminophenyl (**4**) and triazole (**6**) C3 substituted 7-hydroxycoumarins
8 appeared to be the most selective substrates for UGT1A10, an important and often
9 underestimated extrahepatic human UGT. It is concluded that the selectivity of the new
10 coumarin derivatives for UGT1A10 depends on the chemical character of their substituent at
11 C3. These new compounds should enable better, faster, and easier determination of
12 UGT1A10 activity in tissues than was earlier possible. In addition, their further chemical
13 modification could stimulate the development of new tools to explore the active site of
14 different UGT enzymes.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We thank Ms Hannele Jaatinen for excellent expertise in laboratory work. Finnish IT Centre for Science (CSC) is acknowledged for generous computational grant (O.T.P.: jyy2516 and jyy2585). We thank Johanna Mosorin for her valuable contribution in the preparation of recombinant UGTs. The financial support of the academy of Finland (grant no. 137589) and the Sigrid Juselius Foundation (grant no. 4704583) are highly acknowledged.

Author Contributions

R.O.J, H.R., and O.T.P designed the study. S.R., S.N. and O.T.P. performed the modelling. S.K. and J.H. performed the synthesis of molecules. A.P. performed HPLC-MS analysis. R.O.J. performed the experimental measurements. M.F. provided the UGT enzymes and with J.T. prepared the mutant. All the authors contributed to writing of the manuscript.

Declaration of Interest

The authors declare no conflict of interests.

Table 1. Michaelis-Menten (MM) kinetic constants of UGT1A10 and UGT1A10mutant catalyzed 7-hydroxyl glucuronidation for the 3-substituted 7-hydroxycoumarins.

Compound	UGT1A10					UGT1A10mutant				
	K _m (95 % confidence interval) [μM]	V _{max} (95 % confidence interval) [μmol/min/g prot]	V _{max} / K _m [L/min/g prot]	Non-linear MM model R ²	K _m (95 % confidence interval) [μM]	V _{max} (95 % confidence interval) [μmol/min/g prot]	V _{max} / K _m [L/min/g prot]	Non-linear MM model R ²	Non-linear model R ²	
1	10.7 (1.7-19.6)	31 (17-46)	2.9	0.9813	3.5 (0-9.3)	8.7 (3.4-14)	2.5	0.8726	0.8726	
2	2.2 (1-3.4)	5.9 (4.9-6.9)	2.7	0.9788	7.8 (5.5-10.2)	6.3 (5.4-7.3)	0.81	0.9965	0.9965	
3	8.3 (0-31.4)	22.3 (0 – 53.4)	2.7	0.8028	3.8 (0.97-6.7)	9.5 (6.8-12.3)	2.5	0.9695	0.9695	
4	2.8 (0-6.5)	15.3 (7.3-24)	5.5	0.9215	4.7 (1.5-7.9)	6.5 (4.4-8.6)	1.4	0.9846	0.9846	
5	2.8 (0.7-4.9)	16.2 (12-20)	5.8	0.9571	4.6 (1.5-7.8)	5.9 (4.1-7.6)	1.3	0.9750	0.9750	
6	7.0 (3.1-11)	5.3 (3.7-8)	0.76	0.9879	26.8 (0-80)	6.3 (0-15.9)	0.24	0.9733	0.9733	
HFC	14 (10.7-17.3)	15.1 (12.7-17.5)	1.1	0.9991	32.9 (0-102)	11.7 (0-31.7)	0.36	0.9781	0.9781	

Figure legends

Figure 1. Glucuronidation of 7-hydroxycoumarin derivatives. Fluorescent 3-substituted 7-hydroxycoumarins are glucuronidated to non-fluorescent glucuronide conjugates by UGT enzymes. The decrease in fluorescence can be measured conveniently in different kinds of experimental setups.

Figure 2. Docking of 7-hydroxycoumarin and its derivatives into the UGT1A10 model. (A) Molecular docking placed the 7-hydroxycoumarin with the 7-hydroxy facing the catalytic site formed by H37 and UDPGA, enabling the glucuronidation reaction and the subsequent decrease in fluorescence. (B) In UGT1A1, D103 and L106 are not capable of forming similar beneficial interactions with the coumarin core as the UGT1A10 model. Although N102 might be able to form beneficial interactions with certain compounds, the cavity might not be large enough for more sizable substitutions due to N102 and M213. (C) UGT1A8 has otherwise the same amino acid residues aligning the cavity as UGT1A10, except for R103. Due to its size, R103 might impair the binding of the coumarin core. (D) **6** fills the binding cavity (orange solvent accessible surface) of the UGT1A10 model (green solvent accessible surface). Docking suggests that the 7-hydroxycoumarin and **6** have a similar binding mode at their identical core. In addition, the C3 substituent of **6** fits tightly to the additional space at the outward facing end of the binding cavity.

Figure 3. Novel (**1-6**) and control 7-hydroxycoumarin and 7-hydroxy-4-trifluoromethylcoumarin (HCF) substrates of UGT1A enzymes in this study.

Figure 4. Decrease of 7-hydroxycoumarin fluorescence during glucuronidation. Excitation and emission fluorescence spectra of 0.1 μM 7-hydroxy-3-triazolecoumarin at 100 mM phosphate pH 7.4 buffer (panel A); decrease in 10 μM 7-hydroxy-3-triazolecoumarin fluorescence in the presence of 0.7 mg/mL pig liver microsomal protein, 0.5 mM UDPGA, 5

1
2
3 mM MgCl₂ and 100 mM Tris-HCL pH 7.4 (panel B); effect of the amount of microsomal
4 protein on the decrease in fluorescence (panel C); effect of solvents and alamethicin on the
5 decrease in fluorescence (panel D). Corresponding results were obtained with other C7
6 substituted 7-hydroxycoumarin derivatives.
7
8
9
10

11
12 Figure 5. Glucuronidation of C3 substituted 7-hydroxycoumarins by human UGTs.
13
14 Glucuronidation was determined at 10 μM aglycone concentration.
15
16

17
18 Figure 6. Glucuronidation of C3 substituted 7-hydroxycoumarins by human intestinal and
19 hepatic microsomes. Glucuronidation was determined at 10 μM aglycone concentration.
20
21

22
23 Figure 7. Michaelis-Menten kinetics of UGT1A10 (open circle) and UGT1A10 mutant
24 (closed circle) catalyzed 7-hydroxyl glucuronidation for the 3-substituted 7-
25 hydroxycoumarins (**1** – **7** and HFC). The data are from one experiment and the analyzed data
26 are shown in table 1.
27
28
29
30
31
32
33
34

35 **Supporting information**

36
37
38 Supplementary figures and tables.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Jones, C. R.; Hatley, O. J.; Ungell, A. L.; Hilgendorf, C.; Peters, S. A.; Rostami-Hodjegan, A., Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination. *Aaps J* **2016**, *18* (3), 589-604.
2. Gonzalez, F. J.; Coughtrie, M.; Tukey, R. H., Drug Metabolism. In *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 12th edition ed.; Brunton, L. L.; Chabner, B.; Knollman, B., Eds. McGraw-Hill: New York, 2011; pp 123-143.
3. Mizuma, T., Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. *Int J Pharmaceut* **2009**, *378* (1-2), 140-141.
4. Ritter, J. K., Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. *Expert Opin Drug Metab Toxicol* **2007**, *3* (1), 93-107.
5. Wu, B. J.; Kulkarni, K.; Basu, S.; Zhang, S. X.; Hu, M., First-Pass Metabolism via UDP-Glucuronosyltransferase: a Barrier to Oral Bioavailability of Phenolics. *Journal of pharmaceutical sciences* **2011**, *100* (9), 3655-3681.
6. Testa, B.; Kramer, S. D., The biochemistry of drug metabolism--an introduction: part 5. Metabolism and bioactivity. *Chemistry & biodiversity* **2009**, *6* (5), 591-684.
7. Kaivosaaari, S.; Finel, M.; Koskinen, M., N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. *Xenobiotica* **2011**, *41* (8), 652-69.
8. Rowland, A.; Miners, J. O.; Mackenzie, P. I., The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. *The international journal of biochemistry & cell biology* **2013**, *45* (6), 1121-32.
9. Court, M. H.; Zhang, X. L.; Ding, X. X.; Yee, K. K.; Hesse, L. M.; Finel, M., Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. *Xenobiotica* **2012**, *42* (3), 266-277.
10. Ohno, S.; Nakajin, S., Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction. *Drug Metabolism and Disposition* **2009**, *37* (1), 32-40.
11. Sato, Y.; Nagata, M.; Tetsuka, K.; Tamura, K.; Miyashita, A.; Kawamura, A.; Usui, T., Optimized Methods for Targeted Peptide-Based Quantification of Human Uridine 5'-Diphosphate-Glucuronosyltransferases in Biological Specimens Using Liquid Chromatography-Tandem Mass Spectrometry. *Drug Metabolism and Disposition* **2014**, *42* (5), 885-889.
12. Hu, D. G.; Meech, R.; McKinnon, R. A.; Mackenzie, P. I., Transcriptional regulation of human UDP-glucuronosyltransferase genes. *Drug Metab Rev* **2014**, *46* (4), 421-58.
13. Troberg, J.; Jarvinen, E.; Ge, G. B.; Yang, L.; Finel, M., UGT1A10 Is a High Activity and Important Extrahepatic Enzyme: Why Has Its Role in Intestinal Glucuronidation Been Frequently Underestimated? *Mol Pharm* **2016**.
14. Oda, S.; Kato, Y.; Hatakeyama, M.; Iwamura, A.; Fukami, T.; Kume, T.; Yokoi, T.; Nakajima, M., Evaluation of expression and glycosylation status of UGT1A10 in Supersomes and intestinal epithelial cells with a novel specific UGT1A10 monoclonal antibody. *Drug Metab Dispos* **2017**, *45* (9), 1027-1034.
15. Hoglund, C.; Sneitz, N.; Radomska-Pandya, A.; Laakonen, L.; Finel, M., Phenylalanine 93 of the human UGT1A10 plays a major role in the interactions of the enzyme with estrogens. *Steroids* **2011**, *76* (13), 1465-1473.

- 1
2
3 16. Kallionpaa, R. A.; Jarvinen, E.; Finel, M., Glucuronidation of estrone and 16alpha-
4 hydroxyestrone by human UGT enzymes: The key roles of UGT1A10 and UGT2B7. *The Journal of*
5 *steroid biochemistry and molecular biology* **2015**, *154*, 104-111.
- 6 17. Itaaho, K.; Mackenzie, P. I.; Ikushiro, S.; Miners, J. O.; Finel, M., The configuration of
7 the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by
8 human UDP-glucuronosyltransferases. *Drug Metab Dispos* **2008**, *36* (11), 2307-15.
- 9 18. Sneitz, N.; Vahermo, M.; Mosorin, J.; Laakkonen, L.; Poirier, D.; Finel, M.,
10 Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation
11 of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol. *Drug Metab Dispos* **2013**, *41* (3), 582-91.
- 12 19. Itaaho, K.; Court, M. H.; Uutela, P.; Kostianen, R.; Radomska-Pandya, A.; Finel, M.,
13 Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase
14 1A10. *Drug Metab Dispos* **2009**, *37* (4), 768-75.
- 15 20. Raunio, H.; Kuusisto, M.; Juvonen, R. O.; Pentikainen, O. T., Modeling of interactions
16 between xenobiotics and cytochrome P450 (CYP) enzymes. *Front Pharmacol* **2015**, *6*, 123.
- 17 21. Kirchmair, J.; Goller, A. H.; Lang, D.; Kunze, J.; Testa, B.; Wilson, I. D.; Glen, R. C.;
18 Schneider, G., Predicting drug metabolism: experiment and/or computation? *Nature reviews. Drug*
19 *discovery* **2015**, *14* (6), 387-404.
- 20 22. Dai, Z. R.; Feng, L.; Jin, Q.; Cheng, H.; Li, Y.; Ning, J.; Yu, Y.; Ge, G. B.; Cui, J. N.; Yang, L.,
21 A practical strategy to design and develop an isoform-specific fluorescent probe for a target enzyme:
22 CYP1A1 as a case study. *Chem Sci* **2017**, *8* (4), 2795-2803.
- 23 23. Dai, Z. R.; Ge, G. B.; Feng, L.; Ning, J.; Hu, L. H.; Jin, Q.; Wang, D. D.; Lv, X.; Dou, T. Y.;
24 Cui, J. N.; Yang, L., A Highly Selective Ratiometric Two-Photon Fluorescent Probe for Human
25 Cytochrome P450 1A. *J Am Chem Soc* **2015**, *137* (45), 14488-95.
- 26 24. Miley, M. J.; Zielinska, A. K.; Keenan, J. E.; Bratton, S. M.; Radomska-Pandya, A.;
27 Redinbo, M. R., Crystal structure of the cofactor-binding domain of the human phase II drug-
28 metabolism enzyme UDP-glucuronosyltransferase 2B7. *J Mol Biol* **2007**, *369* (2), 498-511.
- 29 25. Rahikainen, T.; Hakkinen, M. R.; Finel, M.; Pasanen, M.; Juvonen, R. O., A high
30 throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant
31 human UDP-glucuronosyltransferases and liver microsomes. *Xenobiotica* **2013**, *43* (10), 853-61.
- 32 26. Modolo, L. V.; Li, L.; Pan, H.; Blount, J. W.; Dixon, R. A.; Wang, X., Crystal structures of
33 glycosyltransferase UGT78G1 reveal the molecular basis for glycosylation and deglycosylation of
34 (iso)flavonoids. *J Mol Biol* **2009**, *392* (5), 1292-302.
- 35 27. Hiromoto, T.; Honjo, E.; Tamada, T.; Noda, N.; Kazuma, K.; Suzuki, M.; Kuroki, R.,
36 Crystal structure of UDP-glucose:anthocyanidin 3-O-glucosyltransferase from *Clitoria ternatea*. *J*
37 *Synchrotron Radiat* **2013**, *20* (Pt 6), 894-8.
- 38 28. Offen, W.; Martinez-Fleites, C.; Yang, M.; Kiat-Lim, E.; Davis, B. G.; Tarling, C. A.; Ford,
39 C. M.; Bowles, D. J.; Davies, G. J., Structure of a flavonoid glucosyltransferase reveals the basis for
40 plant natural product modification. *EMBO J* **2006**, *25* (6), 1396-405.
- 41 29. Lehtonen, J. V.; Still, D. J.; Rantanen, V. V.; Ekholm, J.; Bjorklund, D.; Iftikhar, Z.;
42 Huhtala, M.; Repo, S.; Jussila, A.; Jaakkola, J.; Pentikainen, O.; Nyronen, T.; Salminen, T.; Gyllenberg,
43 M.; Johnson, M. S., BODIL: a molecular modeling environment for structure-function analysis and
44 drug design. *J Comput Aided Mol Des* **2004**, *18* (6), 401-19.
- 45 30. Johnson, M. S.; Overington, J. P., A structural basis for sequence comparisons. An
46 evaluation of scoring methodologies. *J Mol Biol* **1993**, *233* (4), 716-38.
- 47 31. Sali, A.; Blundell, T. L., Comparative protein modelling by satisfaction of spatial
48 restraints. *J Mol Biol* **1993**, *234* (3), 779-815.
- 49 32. Niinivehmas, S. P.; Salokas, K.; Latti, S.; Raunio, H.; Pentikainen, O. T., Ultrafast protein
50 structure-based virtual screening with Panther. *J Comput Aided Mol Des* **2015**, *29* (10), 989-1006.
- 51 33. Korb, O.; Stutzle, T.; Exner, T. E., Empirical scoring functions for advanced protein-
52 ligand docking with PLANTS. *J Chem Inf Model* **2009**, *49* (1), 84-96.
- 53
54
55
56
57
58
59
60

- 1
2
3 34. Niinivehmas, S. P.; Manivannan, E.; Rauhamaki, S.; Huuskonen, J.; Pentikainen, O. T.,
4 Identification of estrogen receptor alpha ligands with virtual screening techniques. *J Mol Graph*
5 *Model* **2016**, *64*, 30-9.
- 6 35. Kirkiacharian, S.; Lormier, A. T.; Resche-Rigon, M.; Bouchoux, F.; Cerede, E., [Synthesis
7 and binding affinity of 3-aryl-7-hydroxycoumarins to human alpha and beta estrogen receptors]. *Ann*
8 *Pharm Fr* **2003**, *61* (1), 51-6.
- 9 36. Buuhoi, N. P.; Ekert, B.; Royer, R., Bz-Hydroxylated-3-Aryl-Coumarins and 3,4-Diaryl-
10 Coumarins. *J Org Chem* **1954**, *19* (9), 1548-1552.
- 11 37. Kurkela, M.; Garcia-Horsman, J. A.; Luukkanen, L.; Morsky, S.; Taskinen, J.; Baumann,
12 M.; Kostiainen, R.; Hirvonen, J.; Finel, M., Expression and characterization of recombinant human
13 UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other
14 UGTs and was purified as an active dimeric enzyme. *J Biol Chem* **2003**, *278* (6), 3536-44.
- 15 38. Kuuranne, T.; Aitio, O.; Vahermo, M.; Elovaara, E.; Kostiainen, R., Enzyme-assisted
16 synthesis and structure characterization of glucuronide conjugates of methyltestosterone (17 alpha-
17 methylandro-4-en-17 beta-ol-3-one) and nandrolone (estr-4-en-17 beta-ol-3-one) metabolites.
18 *Bioconjugate chemistry* **2002**, *13* (2), 194-9.
- 19 39. Sneitz, N.; Court, M. H.; Zhang, X.; Laajanen, K.; Yee, K. K.; Dalton, P.; Ding, X.; Finel,
20 M., Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional
21 characterization in comparison with UGT2A1 and UGT2A3. *Pharmacogenet Genomics* **2009**, *19* (12),
22 923-34.
- 23 40. Kurkela, M.; Patana, A. S.; Mackenzie, P. I.; Court, M. H.; Tate, C. G.; Hirvonen, J.;
24 Goldman, A.; Finel, M., Interactions with other human UDP-glucuronosyltransferases attenuate the
25 consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6.
26 *Pharmacogenet Genomics* **2007**, *17* (2), 115-26.
- 27 41. Lang, M. A.; Gielen, J. E.; Nebert, D. W., Genetic evidence for many unique liver
28 microsomal P-450-mediated monooxygenase activities in heterogeneic stock mice. *J Biol Chem* **1981**,
29 *256* (23), 12068-75.
- 30 42. Kuuranne, T.; Kurkela, M.; Thevis, M.; Schanzer, W.; Finel, M.; Kostiainen, R.,
31 Glucuronidation of anabolic androgenic steroids by recombinant human UDP-
32 glucuronosyltransferases. *Drug Metab Dispos* **2003**, *31* (9), 1117-24.
- 33 43. Zhang, H.; Tolonen, A.; Rousu, T.; Hirvonen, J.; Finel, M., Effects of cell differentiation
34 and assay conditions on the UDP-glucuronosyltransferase activity in Caco-2 cells. *Drug Metab Dispos*
35 **2011**, *39* (3), 456-64.
- 36 44. Lavis, L. D.; Raines, R. T., Bright building blocks for chemical biology. *Acs Chem Biol*
37 **2014**, *9* (4), 855-66.
- 38 45. Lv, X.; Feng, L.; Ai, C. Z.; Hou, J.; Wang, P.; Zou, L. W.; Cheng, J.; Ge, G. B.; Cui, J. N.;
39 Yang, L., A Practical and High-Affinity Fluorescent Probe for Uridine Diphosphate
40 Glucuronosyltransferase 1A1: A Good Surrogate for Bilirubin. *J Med Chem* **2017**, *60* (23), 9664-9675.
- 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Glucuronidation of 7-hydroxycoumarin derivatives. Fluorescent 3-substituted 7-hydroxycoumarins are glucuronidated to non-fluorescent glucuronide conjugates by UGT enzymes. The decrease in fluorescence can be measured conveniently in different kinds of experimental setups.

338x190mm (96 x 96 DPI)




Figure 2. Docking of 7-hydroxycoumarin and its derivatives into the UGT1A10 model. (A) Molecular docking placed the 7-hydroxycoumarin with the 7-hydroxy facing the catalytic site formed by H37 and UDPGA, enabling the glucuronidation reaction and the subsequent decrease in fluorescence. (B) In UGT1A1, D103 and L106 are not capable of forming similar beneficial interactions with the coumarin core as the UGT1A10 model. Although N102 might be able to form beneficial interactions with certain compounds, the cavity might not be large enough for more sizable substitutions due to N102 and M213. (C) UGT1A8 has otherwise the same amino acid residues aligning the cavity as UGT1A10, except for R103. Due to its size, R103 might impair the binding of the coumarin core. (D) 6 fills the binding cavity (orange solvent accessible surface) of the UGT1A10 model (green solvent accessible surface). Docking suggests that the 7-hydroxycoumarin and 6 have a similar binding mode at their identical core. In addition, the C3 substituent of 6 fits tightly to the additional space at the outward facing end of the binding cavity.

1252x1570mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Novel (1-6) and control 7-hydroxycoumarin and 7-hydroxy-4-trifluoromethylcoumarin (HCF) substrates of UGT1A enzymes in this study.

338x190mm (96 x 96 DPI)




Figure 4. Decrease of 7-hydroxycoumarin fluorescence during glucuronidation. Excitation and emission fluorescence spectra of 0.1 μM 7-hydroxy-3-triazolecoumarin at 100 mM phosphate pH 7.4 buffer (panel A); decrease in 10 μM 7-hydroxy-3-triazolecoumarin fluorescence in the presence of 0.7 mg/mL pig liver microsomal protein, 0.5 mM UDPGA, 5 mM MgCl_2 and 100 mM Tris-HCL pH 7.4 (panel B); effect of the amount of microsomal protein on the decrease in fluorescence (panel C); effect of solvents and alamethicin on the decrease in fluorescence (panel D). Corresponding results were obtained with other C7 substituted 7-hydroxycoumarin derivatives.

338x190mm (96 x 96 DPI)




Figure 5. Glucuronidation of C3 substituted 7-hydroxycoumarins by human UGTs. Glucuronidation was determined at 10 μM aglycone concentration.

338x190mm (96 x 96 DPI)




Figure 6. Glucuronidation of C3 substituted 7-hydroxycoumarins by human intestinal and hepatic microsomes. Glucuronidation was determined at 10 μ M aglycone concentration.

338x190mm (96 x 96 DPI)





Figure 7. Michaelis-Menten kinetics of UGT1A10 (open circle) and UGT1A10 mutant (closed circle) catalyzed 7-hydroxyl glucuronidation for the 3-substituted 7-hydroxycoumarins (1 – 7 and HFC). The data are from one experiment and the analyzed data are shown in table 1.

338x190mm (96 x 96 DPI)



Graphic for manuscript

338x190mm (96 x 96 DPI)